News headlines about Sientra (NASDAQ:SIEN) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sientra earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.6723763312361 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- North Korea must stop ‘provocative’ behaviour and we’re ready to protect Guam (fishinghd.com)
- Breast Implants Market – Global Opportunity Analysis and Industry Forecast, 2017-2025 (sbwire.com)
- Forecast and Analysis on Cosmetology Market by Future Market Insights (reports.pr-inside.com)
- Singer Natalie Cole’s Son Robert Yancy Dead at 39 (fishinghd.com)
- Zacks Investment Research Lowers Sientra, Inc. (SIEN) to Sell (americanbankingnews.com)
Shares of Sientra (NASDAQ:SIEN) traded down 0.86% during midday trading on Friday, hitting $10.40. The stock had a trading volume of 72,417 shares. Sientra has a one year low of $6.92 and a one year high of $11.47. The firm has a 50 day moving average price of $10.58 and a 200 day moving average price of $9.02. The stock’s market cap is $200.78 million.
Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.04. The firm had revenue of $8.20 million for the quarter, compared to the consensus estimate of $6.97 million. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. The company’s quarterly revenue was up 32.3% compared to the same quarter last year. On average, equities analysts forecast that Sientra will post ($3.07) earnings per share for the current fiscal year.
Several equities analysts have issued reports on SIEN shares. Lake Street Capital reiterated a “buy” rating and issued a $15.00 target price (up previously from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Stephens started coverage on Sientra in a research note on Tuesday, July 11th. They set an “overweight” rating and a $12.00 price target on the stock.
WARNING: This article was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/sientra-nasdaqsien-earns-daily-media-sentiment-rating-of-0-15-updated.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.